|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2002-7-4
|
|
pubmed:abstractText |
Although continuing antidepressant treatment after patients have responded to medication has been shown to greatly reduce the risk of relapse, this risk is not eliminated. A number of theories have been proposed to account for this apparent loss of efficacy. A common initial approach to managing relapse is to increase the dose of antidepressant. We prospectively evaluated the likelihood of response to increasing the fluoxetine doses in patients relapsing during a long-term efficacy study of two fluoxetine dosing regimens.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0033-3190
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2002 S. Karger AG, Basel
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
71
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
190-4
|
|
pubmed:dateRevised |
2009-11-11
|
|
pubmed:meshHeading |
pubmed-meshheading:12097783-Adult,
pubmed-meshheading:12097783-Depressive Disorder, Major,
pubmed-meshheading:12097783-Dose-Response Relationship, Drug,
pubmed-meshheading:12097783-Double-Blind Method,
pubmed-meshheading:12097783-Drug Administration Schedule,
pubmed-meshheading:12097783-Female,
pubmed-meshheading:12097783-Fluoxetine,
pubmed-meshheading:12097783-Humans,
pubmed-meshheading:12097783-Male,
pubmed-meshheading:12097783-Prospective Studies,
pubmed-meshheading:12097783-Recurrence,
pubmed-meshheading:12097783-Serotonin Uptake Inhibitors,
pubmed-meshheading:12097783-Severity of Illness Index,
pubmed-meshheading:12097783-Tablets, Enteric-Coated
|
|
pubmed:articleTitle |
Treatment approaches to major depressive disorder relapse. Part 1: dose increase.
|
|
pubmed:affiliation |
Lilly Research Laboratories, Indianapolis, Ind 46285, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Multicenter Study
|
